Analyzing R&D Budgets: Bio-Techne Corporation vs Geron Corporation

A Decade of Innovation: R&D Spending in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Bio-Techne Corporation and Geron Corporation have been at the forefront, investing heavily in R&D to drive breakthroughs.

Bio-Techne Corporation: A Steady Climb

From 2014 to 2023, Bio-Techne Corporation's R&D expenses have seen a consistent upward trend, growing by over 200%. This steady increase underscores the company's commitment to innovation and maintaining its competitive edge.

Geron Corporation: A Late Surge

Geron Corporation, on the other hand, experienced a dramatic surge in R&D spending, particularly from 2019 onwards, with a peak in 2023. This late surge, with a 500% increase from 2014, highlights Geron's strategic pivot towards more aggressive research initiatives.

Both companies exemplify the dynamic nature of the biotech industry, where strategic R&D investments are crucial for future success.